Induced Proximity Therapeutics Group
Dr Konopacka's research group focuses on discovery of novel targeted protein degradation therapeutics providing core biology expertise to the Centre for Protein Degradation.
Research, projects and publications in this group
Our group focuses on biology aspects of targeted protein degradation drug discovery and supports the Centre for Protein Degradation in the following areas of research:
1) screening, profiling and molecular mechanisms
of action of molecular glue degraders and PROTACs;
2) enabling novel E3 ligases
for therapeutic applications;
3) target identification and validation.
We are interested in developing innovative induced proximity technologies that expand druggable target space and can generate better and safer treatments for cancer patients.
The IPT team benefits from the extensive cancer research expertise at the ICR, the Royal Marsden Hospital and the Centre for Cancer Drug Discovery, and works closely with medicinal chemists, structural biologists, biophysicists and computational scientists at the CPD, biotech and pharma industry.
Dr Agnieszka Konopacka
Group Leader:
Induced Proximity Therapeutics
Dr Konopacka is the Biology Lead at the Centre for Protein Degradation and Group Leader of the Induced Proximity Therapeutics Group at the Centre for Cancer Drug Discovery.
Researchers in this group
.
Email: [email protected]
Location: Sutton
Bryony joined the IPT team in February 2025 as a Postdoctoral Training Fellow. She completed her PhD at the Patrick G Johnston Centre for Cancer Research in Belfast under the supervision of Dr Lisa Crawford and Dr Rich Williams where she characterised novel inhibitors of the E3 ligase HUWE1 for the treatment of multiple myeloma. Bryony is currently focusing on target validation for CRBN molecular glue degraders and development of novel induced proximity technologies.
.
.